Key result
Prasugrel treatment resulted in a 100% response rate based on VASP-PRI compared to 62-73% in the clopidogrel group, with only 7% of patients in the therapeutic range experiencing major cardiovascular events.
Why the study?
Does VASP flow cytometry assay effectively monitor dual antiplatelet therapy efficacy in patients with acute STEMI post-PCI?
Observational
Does VASP flow cytometry assay effectively monitor dual antiplatelet therapy efficacy in patients with acute STEMI post-PCI?
The VASP-phosphorylation assay may be a relevant method for guiding and tailoring dual antiplatelet therapy in post-PCI STEMI patients by effectively identifying therapeutic platelet reactivity.
Answers are grounded in this paper and cite their sources.
Supports VASP-PRI for tailoring DAPT in STEMI; hypothesis-generating pending randomized confirmation.
INTRODUCTION: Dual antiplatelet treatment (DAPT) with clopidogrel and aspirin represents common approach in prevention of thromboembolic events in patients with acute coronary syndrome undergoing percutaneous coronary intervention (PCI). The drawback of clopidogrel treatment is large interindividual variability in response. AIM: Our article aims to suggesting the most convenient method in monitoring the DAPT of post-PCI patients. METHODS: We analyzed the on-treatment platelet reactivity by light transmission aggregometry and vasodilator-stimulated phosphoprotein (VASP) flow cytometric assay. Samples were obtained in 3 intervals: first prior to PCI, then 1, and 30 days after PCI. RESULTS: Based on VASP-platelet reactivity index (PRI), we observed 100% response rate in prasugrel-treated patients and 62% to 73 % in the clopidogrel group. Overall, only 2 (7%) patients with the VASP-PRI value in therapeutic range had major adverse cardiovascular events. CONCLUSION: Our results hint VASP-phosphorylation assay as a relevant method for guiding and tailoring DAPT.
No takes yet. Share an insight, caveat, or question.
Fedor et al. (2014) conducted an observational in Acute STEMI Post-PCI. Prasugrel vs. Clopidogrel was evaluated on Response rate based on VASP-platelet reactivity index (PRI). Prasugrel treatment resulted in a 100% response rate based on VASP-PRI compared to 62-73% in the clopidogrel group, with only 7% of patients in the therapeutic range experiencing major cardiovascular events.
Synapse has enriched 10 related papers. Consider them for comparative context: